Swiss National Bank acquired a new stake in shares of Athenex Inc (NASDAQ:ATNX) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 55,200 shares of the company’s stock, valued at approximately $1,030,000. Swiss National Bank owned 0.09% of Athenex as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of ATNX. Schwab Charles Investment Management Inc. raised its stake in Athenex by 66.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 210,889 shares of the company’s stock valued at $3,936,000 after acquiring an additional 84,566 shares during the period. Girard Partners LTD. acquired a new position in Athenex in the 2nd quarter valued at $940,000. Strs Ohio grew its holdings in Athenex by 9.9% in the 2nd quarter. Strs Ohio now owns 43,400 shares of the company’s stock valued at $809,000 after buying an additional 3,900 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Athenex by 177.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 163,893 shares of the company’s stock valued at $3,058,000 after buying an additional 104,918 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new position in Athenex in the 2nd quarter valued at $1,681,000. 19.82% of the stock is owned by institutional investors.

A number of research analysts have commented on the company. Zacks Investment Research raised Athenex from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Friday, June 8th. BidaskClub lowered Athenex from a “buy” rating to a “hold” rating in a report on Saturday, May 26th. Finally, ValuEngine lowered Athenex from a “buy” rating to a “hold” rating in a report on Wednesday, June 27th. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $25.33.

In other news, Director Song-Yi Zhang sold 102,734 shares of the stock in a transaction on Wednesday, August 22nd. The stock was sold at an average price of $17.24, for a total transaction of $1,771,134.16. Following the sale, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $68,960. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Johnson Yiu Nam Lau bought 5,000 shares of Athenex stock in a transaction dated Thursday, September 6th. The shares were bought at an average cost of $15.84 per share, for a total transaction of $79,200.00. Following the completion of the acquisition, the chief executive officer now owns 2,825,422 shares in the company, valued at approximately $44,754,684.48. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 12,500 shares of company stock worth $205,425 and sold 344,317 shares worth $5,859,972. Corporate insiders own 29.50% of the company’s stock.

Shares of NASDAQ ATNX opened at $16.46 on Tuesday. Athenex Inc has a one year low of $13.28 and a one year high of $20.90. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -7.09 and a beta of -1.73.

Athenex (NASDAQ:ATNX) last issued its quarterly earnings data on Tuesday, August 14th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.10). Athenex had a negative net margin of 122.29% and a negative return on equity of 73.37%. The firm had revenue of $11.57 million during the quarter. equities research analysts predict that Athenex Inc will post -2 earnings per share for the current year.

Athenex Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Further Reading: Hedge Funds Explained

Institutional Ownership by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.